Intravenous Iron Drugs Market By Product Type (Iron Dextran, Iron Sucrose, Ferric carboxymaltose, Ferumoxytol, Other), By Application (Chronic Kidney Disease Anemia, Iron Deficiency Anemia, Inflammatory Bowel Disease, Cancer-Related Anemia, Other), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic & Infusion Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Product Type

• Iron Dextran
• Iron Sucrose
• Ferric carboxymaltose
• Ferumoxytol
• Other

By Application

• Chronic Kidney Disease Anemia
• Iron Deficiency Anemia
• Inflammatory Bowel Disease
• Cancer-Related Anemia
• Other

By End-User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Diagnostic & Infusion Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Vifor Pharma
• Daiichi Sankyo Company, Limited
• AMAG Pharmaceuticals, Inc.
• American Regent, Inc.
• Pharmacosmos A/S
• Luitpold Pharmaceuticals, Inc.
• Sandoz
• Sanofi S.A.
• Allergan plc
• Shield Therapeutics plc
• Akebia Therapeutics, Inc.
• Rockwell Medical, Inc.
• Zydus Group
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.